NeuroSense Therapeutics Ltd. - *W EXP 11/10/202 (NRSNW)

CUSIP: M74240116

Q4 2023 13F Holders as of 31 Dec 2023

Share change
-28,197
SEC-reported price per share
$0.08
Indexed holders
3
Value change
-$3,283
Number of sells
4

Security key

M74240116

Report period

Q4 2023

Indexed institutions

3

Top holders

3

Ownership snapshot

Top reported holders of NRSNW - NeuroSense Therapeutics Ltd. - *W EXP 11/10/202 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
0/9
Latest evidence
30 Sep 2023
13F Highest disclosed value: $470,020 9 rows are not safely comparable across share classes. Showing 1-6 of 9 holder rows.

Quick read

ARMISTICE CAPITAL, LLC has the largest disclosed position value at $470K.

0 of 9 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Disclosed position value Top 5
ARMISTICE CAPITAL, LLC $470K
MEITAV INVESTMENT HOUSE LTD $67.4K
Hudson Bay Capital Management LP $13.9K
Warberg Asset Management LLC $11K
CITADEL ADVISORS LLC $10.6K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 9 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
ARMISTICE CAPITAL, LLC
13F
Company
13F
—
denominator unverified
$470,020
662,000 shares
— 30 Sep 2023
MEITAV INVESTMENT HOUSE LTD
13F
Company
13F
—
denominator unverified
$67,450
95,000 shares
— 30 Sep 2023
Hudson Bay Capital Management LP
13F
Company
13F
—
denominator unverified
$13,880
86,753 shares
— 30 Sep 2023
Warberg Asset Management LLC
13F
Company
13F
—
denominator unverified
$11,040
76,109 shares
— 30 Sep 2023
CITADEL ADVISORS LLC
13F
Company
13F
—
mixed-class rows
$10,631
23,290 shares
mixed-class rows
— 30 Sep 2023
CLEAR STREET LLC
13F
Company
13F
—
denominator unverified
$9,181
59,272 shares
— 30 Sep 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
3
Shares
209,527
Indexed holders
3
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q4 2023 vs Q3 2023 Across Filers

Q3 2023 indexed holders
6
Q4 2023 indexed holders
3
Indexed holder difference
-3
Investor Q3 2023 Shares Q4 2023 Shares Share Diff Share Chg % Q3 2023 value Q4 2023 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .